Nelonemdaz is an experimental drug that works as a
free radical reducer and selective antagonist of the
NMDA receptor 2b. It is hypothesized to have neuroprotective effects in people who recently experienced a
stroke.[1][2][3][4]
^Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Kwon, Sun U (February 2023). "Abstract TP15: Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion". Stroke. 54 (Suppl_1).
doi:
10.1161/str.54.suppl_1.TP15.
S2CID256564237.
Nelonemdaz is an experimental drug that works as a
free radical reducer and selective antagonist of the
NMDA receptor 2b. It is hypothesized to have neuroprotective effects in people who recently experienced a
stroke.[1][2][3][4]
^Lee, Jin Soo; Lee, Ji Sung; Gwag, Byoung Joo; Choi, Dennis W; An, Chun San; Kang, Hyun Goo; Song, Tae-Jin; Ahn, Seong Hwan; Kim, Chang Hun; Kwon, Sun U (February 2023). "Abstract TP15: Rationale And Ongoing Status In A Phase 3 Trial Of Nelonemdaz, A Novel Neuroprotection Drug, For Patients With Acute Ischemic Stroke And Reperfusion". Stroke. 54 (Suppl_1).
doi:
10.1161/str.54.suppl_1.TP15.
S2CID256564237.